Pharming Group (NASDAQ:PHAR - Get Free Report) shares shot up 6.7% during trading on Friday . The company traded as high as $11.97 and last traded at $11.96. 1,508 shares were traded during trading, a decline of 77% from the average session volume of 6,422 shares. The stock had previously closed at $11.21.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on PHAR. Oppenheimer boosted their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th.
Read Our Latest Analysis on Pharming Group
Pharming Group Price Performance
The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $803.45 million, a P/E ratio of -45.42 and a beta of 0.02. The company's 50-day simple moving average is $9.27 and its 200 day simple moving average is $9.03.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. The company had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, sell-side analysts expect that Pharming Group will post -0.2 earnings per share for the current fiscal year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
